Morgan Stanley
VAXX

Morgan Stanley’s Vaxxinity, Inc. Class A Common Stock VAXX Stock Holding History

Morgan Stanley’s Portfolio VAXX Stock Details VAXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-62,229
Closed -$44.6K – 8039
2024
Q1 		$44.6K Sell
62,229
-168,287
-73% -$122K ﹤0.01% 6258
2023
Q4 		$196K Buy
230,516
+194,045
+532% +$187K ﹤0.01% 5712
2023
Q3 		$50K Sell
36,471
-11,830
-24% -$25.6K ﹤0.01% 6170
2023
Q2 		$122K Buy
48,301
+34,825
+258% +$73.8K ﹤0.01% 5859
2023
Q1 		$30.6K Buy
13,476
+8,950
+198% +$22.7K ﹤0.01% 6466
2022
Q4 		$6.34K Sell
4,526
-3,907
-46% -$6.56K ﹤0.01% 7089
2022
Q3 		$16K Sell
8,433
-2,945
-26% -$6.13K ﹤0.01% 6901
2022
Q2 		$18K Buy
11,378
+3,561
+46% +$13.5K ﹤0.01% 7033
2022
Q1 		$34K Sell
7,817
-3,385
-30% -$18.7K ﹤0.01% 6891
2021
Q4 		$63K Buy
+11,202
New +$116K ﹤0.01% 6700

Other funds holding VAXX

SWM
Spire Wealth Management Mclean, Virginia $3.31B AUM 38.78% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
CGL
Clarius Group LLC Seattle, Washington $1.75B AUM 19.04% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
RF
Robinswood Financial Kirkland, Washington $349M AUM 14.9% 1-Year Est. Return

Morgan Stanley's VAXX Position: Q2 2024 in Review

Morgan Stanley sold out of Vaxxinity, Inc. Class A Common Stock (VAXX) in Q2 2024, closing a stake of 62,229 shares — an estimated $44.6K sold.

Morgan Stanley first reported a position in VAXX in Q4 2021 and held it in 10 quarters. The position peaked at $196K in Q4 2023. 8 funds tracked by Wall St. Rank hold VAXX as of Q2 2024.

  • Morgan Stanley reported no remaining Vaxxinity, Inc. Class A Common Stock position as of Q2 2024 after selling out during the quarter.
  • Morgan Stanley sold 62,229 Vaxxinity, Inc. Class A Common Stock shares in Q2 2024, an estimated $44.6K.
  • Morgan Stanley first reported a position in Vaxxinity, Inc. Class A Common Stock in Q4 2021 and held it in 10 quarters.
  • Morgan Stanley's Vaxxinity, Inc. Class A Common Stock position peaked at $196K in Q4 2023.
  • 8 funds tracked by Wall St. Rank held Vaxxinity, Inc. Class A Common Stock as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.